• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Nonsurgical sterilization technique shows promise as safe, effective alternative to castration

June 29, 2012
Heather Biele, DVM

Injectable chemical compound offers time, money and resource-saving benefits, especially for high-volume veterinary facilities.

Veterinary clinics and animal shelters across the country could soon be streamlining their canine castration protocols, thanks to a product that's gaining popularity in the veterinary community. A nonsurgical, injectable sterilant for male dogs is scheduled for release in the United States this year and could prove to be stiff competition for the traditional surgical method of castration.

Zeuterin, a chemical compound of zinc gluconate neutralized with arginine, has been in use in Mexico, Colombia, Bolivia and Panama for a few years under the name Esterilsol and has proven to be a successful method of sterilization in male dogs at least three months of age, according to Ark Sciences, the company that developed the product. Now scheduled for release in the U.S., the injectable formulation is being marketed to induce permanent sterility without the need for general anesthesia or a surgical incision. It is currently FDA-approved for use in dogs three to ten months of age and is available only to licensed veterinarians who are trained by Ark Sciences in the injection technique. Sandeep Manchanda, a member of Ark Science's executive team, says the company is focusing heavily on educating and training veterinarians about the product and the administration technique.

According to Ark Sciences, the product acts as a spermicide and results in permanent and irreversible fibrosis of the testicles. The testicles eventually atrophy and diminish in size, although they will still be visible. As such, animals that are sterilized with this technique are tattooed in the groin area to indicate that they've had the procedure performed. Although infrequent, clinical side effects have been reported to be associated with the product and include testicular swelling and pain, vomiting and injection site reactions. However, the company asserts that proper technique and light sedation for the animal can decrease the occurrence of some of these adverse effects.

Ark Sciences is focusing its initial launch efforts on the nonprofit sector and already has product training in place for a number of shelters and spay-neuter clinics across the country. Additionally, Zeuterin has generated interest from many animal welfare groups and organizations such as the Alliance for Contraception in Cats and Dogs (ACC&D), a group whose core mission is to advance development of nonsurgical sterilization in cats and dogs.

Karen Green, senior director of ACC&D, has been following the development and use of the product internationally for years and is looking forward to its pending release in the United States. "In the U.S., the greatest potential is that it can save many organizations a lot of time, money and space. One of the limitations for some spay-neuter programs is recovery space for animals after surgery. With Zeuterin, the animals don't have to undergo anesthesia and they can be up and ready to leave pretty quickly, since it's an outpatient procedure. That can make it possible for organizations to use fewer resources to sterilize male dogs, leaving them with more resources for spaying females or for their other programs, such as adoption or education."

Advertisement

But even the strongest proponents of the product realize that it may take time for the veterinary industry—private practitioners in particular—to embrace this form of sterilization. "It's a bit of a paradigm shift," says Byron Maas, DVM, a master trainer for the product. "Veterinarians already have the tools to do surgical spays and neuters, so why change? The fact is, some clients may be worried about anesthesia or the invasiveness of surgery. There is a market for this type of neutering in the veterinary community and we, as veterinarians, can offer it to clients as an alternative to traditional castration." Maas, who is also a private practitioner in Bend, Ore., and a longtime advocate for population control in companion animals, stresses that this product is different because it's being made available only to trained veterinarians. "The focus is on the veterinarian understanding the product and using it correctly," he says.

Ultimately, Ark Sciences hopes that Zeuterin will overcome the barriers known to prohibit reduction in the intact dog population, such as time, money and available resources. "We may be able to get to a larger population of male dogs that surgery alone hasn't been able to," Manchanda says. "Our vision and goal is full adoption of any dog that is considered adoptable in this country."

Ark Sciences expects to launch Zeuterin by the end of 2012. More information on the product can be found at www.arksciences.com.

Related Content:

MedicalBreaking News
Drug for acute onset of canine pancreatitis is launched on the US market
Drug for acute onset of canine pancreatitis is launched on the US market
Diagnostics for a thoracic trauma patient
Diagnostics for a thoracic trauma patient
Most important advice this veterinarian received in rehabilitative medicine
Most important advice this veterinarian received in rehabilitative medicine

Advertisement

Latest News

Pride, representation, and inclusion in vet med

Partnership to promote diversity in veterinary medicine and more

Morris Animal Foundation accepting canine cancer research proposals

AI-enhanced MyLabX90VET ultrasound system unveiled

View More Latest News
Advertisement